Explore more publications!

Press Releases

Good Hands Home Care Selects Express Wages to Bring Flexible Pay Access to Its Workforce
Las Palapas Kicks Off 2026 with New Loyalty, Mobile, Ordering & More from Paytronix
Terracon Receives 2025 EBJ and CCBJ Business Achievement Awards
UNITAR Equips 35 Young Entrepreneurs from Egypt, Iraq, and Lebanon with Essential Skills in Business and Innovation

UNITAR Equips 35 Young Entrepreneurs from Egypt, Iraq, and Lebanon with Essential Skills in Business and Innovation

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Mondelēz International Showcases Structurally Stronger Business and Confidence in Reaccelerating Profitable Growth at 2026 CAGNY Conference
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Genmab Publishes 2025 Annual Report
ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
TEXTURED & THRIVING: HUE AFFAIR CELEBRATES 10 YEARS OF AMPLIFYING BLACK BEAUTY
Food Pathogen Testing Market Expected to Expand as Innovative Molecular Diagnostic Tools Become More Widely Adopted
Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
CIMMYT Signs Joint Statement on Food Security at the Munich Security Conference
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions